Long COVID
242
50
73
105
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Published Results
21 trials with published results (9%)
Research Maturity
105 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.2%
3 terminated out of 242 trials
97.2%
+10.6% vs benchmark
3%
8 trials in Phase 3/4
20%
21 of 105 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 105 completed trials
Clinical Trials (242)
Heat thErapy And mobiLity in COVID-19 Survivors
Long COVID Immune Profiling
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
QEEG-NEUROFEEDBACK FOR COGNITIVE REHABILITATION IN LONG COVID-19 SURVIVORS WITH BRAIN FOG
A Study to Examine Anktiva for the Treatment of COVID-19.
Etiology Analysis of Chronic Cough After COVID-19 Infection and Research on the Efficacy of ICS or ICS/LABA
NE3107 in Adults With Neurological Symptoms of Long COVID
Taurine Supplementation in Long COVID
Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19
Development of Voice Biomarkers of Frequent COVID-19 and Long Covid-related Symptoms Based on Data From Users of the Long COVID Companion App
Evaluation of the Effectiveness of Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital
Long-Term Health Effects of Previous Coronavirus Disease 2019 (COVID-19) in Patients Undergoing Preoperative Anesthesia Evaluation
Long-Covid-19 Alleviation Through Learning Mindfulness Study
Understanding Patterns of Fatigue in Health and Disease
Nitrite Supplementation in Long COVID Patients
Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid
Fatigue Investigation Using Digital Outcomes
PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Validation of Biomarkers for Long COVID in the LIINC Viral Immunopathogenesis and Persistence Repeat Donor Cohort (VIPER)
AT1001 for the Treatment of Long COVID